<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587947</url>
  </required_header>
  <id_info>
    <org_study_id>Entresto</org_study_id>
    <nct_id>NCT04587947</nct_id>
  </id_info>
  <brief_title>Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study</brief_title>
  <official_title>Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Josefs-Hospital Wiesbaden GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Josefs-Hospital Wiesbaden GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor with the ability to&#xD;
      reduce myocardial hypertrophy, cardiac remodeling and cardiorenal fibrosis. The compound is&#xD;
      also believed to have antiarrhythmic properties as it has been shown to significantly reduce&#xD;
      ventricular arrhythmias in patients with implantable cardioverter defibrillators.&#xD;
&#xD;
      Patients suffering from heart failure with reduced ejection fraction show impaired heart rate&#xD;
      variability, knowing that in these patients such impairment is highly associated with an&#xD;
      increased risk of sudden cardiac death.&#xD;
&#xD;
      In its pivotal study, sacubitril/valsartan demonstrated a significant advantage over&#xD;
      enalapril in terms of cardiovascular mortality and rehospitalization.&#xD;
&#xD;
      Against this background, this study was designed to analyze the largely unknown&#xD;
      electrophysiological effects of sacubitril/valsartan on the autonomic cardiac nervous system&#xD;
      by determining heart rate variability.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in heart rate variability</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in heart rate variability after 3 months of treatment with sacubitril/ valsartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in left ventricular ejection fraction (%)</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in left ventricular ejection fraction (%) assessed by transthoracic echocardiogramChanges in echocardiographic parameters (left ventricular parameters)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in mitral insufficiency grade</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in mitral insufficiency grade assessed by transthoracic echocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in serum NT-proB-Type natriuretic peptide (ng/l)</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in laboratory parameters (serum NT-proB-Type natriuretic peptide (ng/l)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Serum creatinine level (mg/dl)</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in laboratory parameters (Serum creatinine level (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in glomerular filtration rate (ml/min)</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in laboratory parameters (glomerular filtration rate ml/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in serum potassium level (mmol/l)</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in laboratory parameters (glomerular filtration rate ml/min)</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure Patients</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sacubitril/ valsartan</intervention_name>
    <description>Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic severe heart failure with reduced ejection fraction (LVEF&#xD;
             â‰¤40%,)&#xD;
&#xD;
          -  Age &gt; 20 years&#xD;
&#xD;
          -  Consent capacity&#xD;
&#xD;
          -  Sinus rhythm&#xD;
&#xD;
          -  Suitable for a drug conversion from AT1/ACE inhibitors to sacubitril/ valsartan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lack of consent capacity&#xD;
&#xD;
          -  Contraindications for a therapy with sacubitril/ valsartan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joachim Ehrlich, MD</last_name>
    <phone>+496111771201</phone>
    <email>jehrlich@joho.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Boehmer, MD</last_name>
    <phone>+496111771201</phone>
    <email>aboehmer@joho.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Josefs-Hospital Wiesbaden GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Ehrlich, Prof. Dr.</last_name>
      <phone>+496111771201</phone>
      <email>jehrlich@joho.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Boehmer, Dr. med.</last_name>
      <phone>+496111771201</phone>
      <email>aboehmer@joho.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

